An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
VERDICT
The label
Accumulation
read at $41.03
Apellis Pharmaceuticals, Inc. holds its Accumulation at $41.03.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
STUDY
Titan case study · our full written analysis of APLS
Elevated stress, defensive posture warranted, held for 12 days
Price
$41.03
Valuation
38.35 trailing · -130.55 forward price to earnings
Values screen
PASS· score 93.6
Beta
-0.25
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads FAIR VALUE — it trades above our $41.00 fair value estimate, 60.90% revenue growth.
Read at
$41.03
38.35 P/E · -130.55 fwd
Our fair value
$41.00
0% premium
Analyst target (avg)
$41.00
-0% to current
Target low $40.00Analyst target rangeTarget high $41.00
▲ current $41.03 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$41.03
you are here
Conservative
$40.00
-3%
Analyst avg
$41.00
-0%
Our fair value
$41.00
-0%
Analyst high
$41.00
-0%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our model and the Street both land near today's price — fairly valued, with no strong edge either way.
Revenue growth
60.90%
Profit margin
12.06%
Debt to equity
114.66
Analyst consensus
Hold · 13 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 9.1% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 7.7% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Biotech firm priced exactly at fair value
Picture a commercial-stage drug maker finally turning high unmet needs into real sales. Apellis has delivered 61% revenue growth and a 12% profit margin while posting a striking 46% return on equity. Those numbers explain why the shares sit right at our calculated fair value with zero margin of safety.
The business clears our ethical screen and the analyst consensus lines up with a hold rating and a median target matching the current price. Forward earnings are still negative, however, so the strong recent profitability has yet to translate into sustained positive forecasts.
Risk sits in the usual biotech uncertainties around future trial outcomes and reimbursement, plus the fact that a negative forward multiple leaves little room for disappointment. The market is not offering a bargain or a clear overvaluation at these levels. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
APLS trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41. Entered 2026-07-21 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-21Accumulation$41.03+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-18Accumulation$41.03+0.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-17Accumulation$41.03+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-03Accumulation$41.03+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$41.03Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
